EUVIMEDEUVIMED entdecken
Crossref

Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials

Kaoutar Abbou Oucherif, Shiven Kapur, Ronghua Bei, Shawn Berens, Patricia L Brown-Augsburger

Pharmaceutical Research · 2025

DOI: 10.1007/s11095-025-03907-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2025. Verfasst von Kaoutar Abbou Oucherif und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA. abbou_oucherif_kaoutar@lilly.com. Hauptthemen laut MEDLINE: Injection Site Reaction, Disease Models, Animal. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Injection site reactions (ISRs), including edema, erythema, pruritus, and pain, impact patient experience and drug tolerability. ISRs are commonly observed and pose challenges in therapeutic development, yet no non-clinical model exists for screening and derisking them before human trials. To fill in this gap, we sought to evaluate the minipig as a non-clinical model for ISRs. METHODS: The minipig model was assessed using six ISR-inducing molecules (positive controls) and two placebos with matching formulations (negative controls). Additionally, to evaluate the physiological similarity between minipigs and humans, we tested whether antihistamine pre-treatment, which is known to reduce ISRs in humans, had a similar effect in minipigs. RESULTS: The minipig model consistently responded to all six positive control molecules, though at higher doses than in humans. Minor ISRs occurred in a quarter of the negative controls but their frequency and/or severity was easily distinguishable from positive controls. Antihistamine pre-treatment effectively reduced ISR severity. CONCLUSION: Our results suggest that the minipig model shows promise for non-clinical screening of high-risk molecules. If a molecule consistently triggers ISRs in the minipig model, phase-appropriate derisking and/or mitigation strategies are warranted. We note that the minipig model is often used for other purposes during pre-clinical subcutaneous drug development; therefore, adding ISR readouts to existing studies would incur minimal operational burden and cost. In summary, our results indicate the potential value of the minipig model in pre-clinical ISR risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Injection Site ReactionDisease Models, AnimalAnimalsSwine, MiniatureSwineHumansHistamine AntagonistsFemaleMaleDrug Evaluation, PreclinicalClinical Trials as Topic

Stichwörter der Autor:innen

ISRInjection site reactionMinipig animal modelSubcutaneous injection

Substanzen

Histamine Antagonists

Autor:innen und Institutionen

  • Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA. abbou_oucherif_kaoutar@lilly.com.
  • Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.

Zitieren

APA

Abbou Oucherif, K., Kapur, S., Bei, R., Berens, S., & Brown-Augsburger, P. L. (2025). Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials. Pharmaceutical Research. https://doi.org/10.1007/s11095-025-03907-2

Vancouver

Abbou Oucherif K, Kapur S, Bei R, Berens S, Brown-Augsburger PL. Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials. Pharmaceutical Research. 2025. doi:10.1007/s11095-025-03907-2

BibTeX
@article{AbbouOucherif2025,
  author = {Abbou Oucherif, Kaoutar and Kapur, Shiven and Bei, Ronghua and Berens, Shawn and Brown-Augsburger, Patricia L},
  title = {Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials},
  journal = {Pharmaceutical Research},
  year = {2025},
  doi = {10.1007/s11095-025-03907-2}
}
Kostenlos starten →